靶向药物治疗儿童中重度特应性皮炎的临床研究进展  

Clinical Research Progress of Targeted Drug Therapy for Children with Moderate to Severe Atopic Dermatitis

作　　者：沈燕[1] 赵华伟 缪静[1,2] SHEN Yan;ZHAO Huawei;MIAO Jing(Research Center for Clinical Pharmacy,Zhejiang University,Hangzhou 310058,China;Department of Pharmacy,Children’s Hospital,Zhejiang University School of Medicine,National Clinical Research Center for Child Health,Hangzhou 310052,China)

机构地区：[1]浙江大学临床药学研究中心,杭州310058 [2]浙江大学医学院附属儿童医院药剂科、国家儿童健康与疾病临床医学研究中心,杭州310052

出　　处：《中国现代应用药学》2024年第9期1287-1294,共8页Chinese Journal of Modern Applied Pharmacy

基　　金：浙江省自然科学基金重点项目(LZ23H030002);浙江省新一轮卫生高层次人才培养工程(2021年度医坛新秀)。

摘　　要：特应性皮炎(atopic dermatitis,AD)是一种以湿疹和皮肤瘙痒为特征的慢性皮肤病,是儿童最常见的皮肤病之一。AD的治疗目前以药物治疗为主,但儿童患者尤其是中重度AD患者的治疗需求尚未被完全满足,安全、有效的长期治疗方案仍待探索实践。以生物制剂和小分子抑制剂为代表的靶向药物是治疗中重度特应性皮炎的新兴药物,本文检索近年来国内外相关文献,分别从生物制剂和小分子抑制剂两方面进行综述,为儿童中重度特应性皮炎靶向药物的进一步开发与应用提供参考。Atopic dermatitis(AD)is a chronic skin disease characterized by eczema and itching,and is one of the most common skin diseases in children.The treatment of AD is currently mainly based on drug therapy,but the treatment needs of children,especially those with moderate to severe AD,have not been fully met,safe and effective long-term treatment plans still need to be explored and practiced.Targeted drugs represented by biological agents and small molecule inhibitors are emerging drugs for the treatment of moderate to severe atopic dermatitis.Referring to relevant literature both domestically and internationally in recent years,this review focuses on two aspects:biological targeting agents and small molecule inhibitors,providing a foundation for the further development and application of targeted drugs for children with moderate to severe atopic dermatitis.

关 键 词：儿童 特应性皮炎 生物制剂 Janus激酶抑制剂 磷酸二酯酶-4抑制剂 临床试验 

分 类 号：R969.3[医药卫生—药理学]